Description
Tiludronic acid belongs to the bisphosphonate therapeutic class,
a class of products with activity on bone metabolism. The main
pharmacological property of TILDREN lnjection is to reduce bone
resorption by inhibiting the activity of osteoclasts.
TILDREN lnjection acts as a regulator of bone remodelling in all
situations involving excessive bone resorption. This regulator effect
is not associated with a negative effect on bone formation or bone
mineralisation at the recommended therapeutic dosage.
Areas of reduced bone density are a pathological change common
to most cases of Navicular Disease and Bone Spavin and are due to
inappropriate resorption of bone (“osteolysis”). In double-blind,
placebo-controlled clinical trials for both conditions, TILDREN treatment
produced clear improvement as demonstrated by long-term reduction
in lameness and progressive resumption of sporting activity.
In another double-blind, placebo-controlled clinical trial into the
treatment of back pain associated with bony lesions of the vertebral
column, TILDREN treatment induced a clear improvement in back
flexibility, however further research is required to add this indication as
a registered claim. Other studies have shown that TILDREN treatment
can prevent the bone loss which usually occurs during inactivity in
horses, as shown by measurements of bone density in spelling horses.
TILDREN lnjection has also demonstrated anti-arthritic properties in a
model of poly-arthritis in rats. In vitro data identified inhibiting effects
on the secretion of enzymes which degrade cartilage matrix.
INDICATIONS
Treatment of lameness associated with bone changes such as those
observed in Navicular Disease and Bone Spavin.
DOSAGE AND ADMINISTRATION
Dosage: 0.1 mg Tiludronic acid per kg bodyweight once daily for 10 days
by slow intravenous injection i.e. 10mL (1 vial) of reconstituted solution
per 500 kg bodyweight per day for 10 days.
Short-term side-effects such as benign muscle tremor, sweating or colic
may occur in a small proportion of horses in the 1-3 hours following
Tiludronic acid injection. These effects generally resolve spontaneously
without specific treatment however observation of the horse for 3 hours
post-injection is recommended.
The incidence of these signs is greatly reduced by slowing down the
speed of administration.
WARNINGS
Due to the lack of studies on the adverse effects of Tiludronic acid on the
skeleton of young animals, this product is not recommended in horses
younger than 2 years of age.
Safety in pregnant or lactating mares has not been established.
Meat Withholding Period: NOT TO BE USED in horses that will be
slaughtered for human consumption.
When administering to competition horses, ensure that the regulations
of relevant authorities are observed.
